Anti-DR5 TNFRSF10B Antibody

Western Blot Validation in Human Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: DR5 A00410-2, (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation in Human HepG2 Cells
Loading: 15 μg of lysates per lane. Antibodies: DR5 A00410-2, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL Lane 2: 2 μg/mL Lane 3: 4 μg/mL

Western Blot Validation in Mouse and Rat Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: DR5 A00410-2, (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP

Western Blot Validation in Mouse Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: DR5 A00410-2, (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation in Mouse Heart
Loading: 15 μg of lysatesper lane. Antibodies: DR5 A00410-2, (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation in Rat Skeletal Muscle
Loading: 15 μg of lysate per lane. Antibodies: DR5 A00410-2, (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Immunofluorescence Validation of DR5 in Human HepG2 Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed human HepG2 cells labeling DR5 with A00410-2 at 5 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).

Immunofluorescence Validation of DR5 in Human Testis
Immunofluorescent analysis of 4% paraformaldehyde-fixed human testis tissue labeling DR5 with A00410-2 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).

Immunofluorescence Validation of DR5 in Mouse Pancreas
Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse pancreas tissue labeling DR5 with A00410-2 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).

Immunofluorescence Validation of DR5 in Rat Brain
Immunofluorescent analysis of 4% paraformaldehyde-fixed rat brain tissue labeling DR5 with A00410-2 at 5 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI (blue).

KO Validation of DR5 in HCT116 Cells (Han et al., 2015)
Anti-cancer drug, Carfilzomib (CFZ), induced up-regulation of DR5 and the expression of DR5 was not detected in DR5-KO HCT 116 cell line with anti-DR5 antibodies (A00410-2).

KD Validation of DR5 in MB231 Cells (Rahman et al., 2009)
Western blot analysis with anti-DR5 antibodies was performed for DR5 in MB231 cells transfected with control siRNA or DR5 siRNA. DR5 expression was disrupted after DR5 siRNA knockdown.

Immunohistochemistry Validation of DR5 in Mouse kidney tissue
Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-DR5 antibody (A00410-2) at 5μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Immunohistochemistry Validation of BIM in Human Colon Tumors (Devetzi et al., 2016)
Protein analysis for DR5 by immunohistochemistry with anti-DR5 antibodies in human colon tumors. Strong immunoreactivity is shown for DR5 in T167 patient with colorectal cancer.

Regulated Expression Validation of DR5 in Thyroid Epithelial Cells (Bretz et al., 2002)
Immunostaining with anti-DR5 antibodies shows high levels of DR5 expression in untreated cells and cells treated with each of the three cytokines alone or TNFalpha combined with IL-1b. In contrast, treatment with both IFNg and TNFalpha or all three cytokines greatly reduces DR5 staining. The reduction in staining appears most significant in cytoplasmic regions while some staining is maintained in or around the nucleus.